



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/00		A2	(11) International Publication Number: WO 99/13864		
(21) International Application Number: PCT/US98/19658		(11) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
(22) International Filing Date: 18 September 1998 (18.09.98)					
(30) Priority Data: 60/059,408 19 September 1997 (19.09.97) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>			
(71) Applicant: SHIRE LABORATORIES, INC. [US/US]; 1550 East Guide Drive, Rockville, MD 20850 (US).					
(72) Inventors: BURNSIDE, Beth, A.; 1808 Briggs Chaney Road, Silver Spring, MD 20905 (US). MC GUINNESS, Charlotte, M.; 6510 Broxborn Drive, Bethesda, MD 20817 (US). RUDNIC, Edward, M.; 15103 Gravenstein Way, North Potomac, MD 20878 (US). COUCH, Richard, A.; Apartment 1021, 7620 Old Georgetown Road, Bethesda, MD 20814 (US). GUO, Xiaodi; 7201 Dubuque Court, Rockville, MD 20855 (US). TUSTIAN, Alexander, K.; Apartment 1302, 3927 243rd Place, Northeast, Bothell, WA 98021 (US).					
(74) Agents: OLSTEIN, Elliot, M. et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).					
(54) Title: SOLID SOLUTION BEADLET					
(57) Abstract					
<p>Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent, which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100 °C, and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolized glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.</p>					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SOLID SOLUTION BEADLET

This application is based on U.S. application serial no. 60/059,408 filed September 19, 1997, the priority of which is claimed.

The present invention relates to the field of pharmaceutical delivery formulations and, more particularly, to those providing rapid release of the therapeutic agent upon oral delivery.

Background of the Invention

A variety of methods for forming micropellets are known in the art. See Kennedy and Niebergall, Development and Optimization of a Solid Dispersion Hot-Melt Fluid Bed Coating Method, *Pharmaceutical Development and Technology*, 1(1):51-62(1996); Hincal and Kas, Preparation of Micropellets by Spray Conegaling, in *Multiparticulate Oral Drug Delivery*, Ghebre-Sellassie (Ed.), Marcel Dekker, Inc. NY, pgs. 17-34 (1994); Eldem *et al.*, Polymorphic of Sprayed Lipid Micropellets and its Evaluation by Differential Scanning Calorimetry and Scanning Electron Microscopy, *Pharmaceutical Research*, 8(2):178-184 (1991); Eldem *et al.*, Optimization of Spray Dried and -Conealed Lipid Micropellets and Characterization of Their Surface Morphology by Scanning Electron Microscopy, *Pharmaceutical Research*, 8(1):47-54 (1991); and Deasy, Spray Drying, Spray Conegaling, Spray Embedding and Spray Condensation, in *Microencapsulation and Related Drug Processes*, Marcel Dekker, Inc., NY, pgs. 181-193 (1984).

Summary of the Invention

In accordance with an aspect of the present invention, there is provided a composition including at least one therapeutic agent and a pharmaceutically acceptable carrier in the form of a solid beadlet wherein the beadlet includes a

combination of at least one hydrophobic long chain fatty acid or fatty acid ester and at least one surfactant. The hydrophobic long chain fatty acid or ester thereof and surfactant are present in the beadlet as a solid solution. The therapeutic agent is dispersed in the solid beadlet and is present in the composition in a therapeutically effective amount, with such amount generally being at least 0.001%, by weight, of the composition.

The hydrophobic long chain fatty acid or ester thereof is generally present in an amount of at least 20% with such material in most cases being present in an amount no greater than 97%, by weight.

The beadlet(s) generally has a particle size that does not exceed 1000 microns. In most cases, the particle size is at least 50 microns. In one embodiment, the particle size does not exceed 500 microns. In another embodiment, the particle size is from 100 to 350 microns.

In a preferred embodiment, the surfactant is one that is liquid at room temperature in that a liquid surfactant in the composition of the invention provides for improved drug delivery.

The surfactant may comprise at least 3% of the core beadlet formulation and in many cases exceeds 10% of the core beadlet formulation all by weight.

The beadlet is preferably in the form of a solid solution wherein the therapeutic agent is dissolved in the hydrophobic material.

In one aspect, the invention provides a solid solution beadlet (used synonymously with granule or particle) comprising (i) at least about 20% by weight of a hydrophobic long chain fatty acid or ester material; (ii) from about 3% to about 40% by weight of a surfactant; and (iii) from about 1% to about 70% by weight of a therapeutic agent, which in admixture form a solid solution at room temperature.

The long chain acids used as an acid or ester generally include at least 12 carbon atoms and generally do not include more than 22 carbon atoms. The acids may

be saturated or unsaturated and generally are aliphatic long chain acids. When used as an ester, the ester is preferably a glycerol ester. The ester may be a mono-, di or tri-ester of glycerol.

The hydrophobic material is preferably oleic acid, gadoleic acid, eurcic acid, linoleic acid, linolenic acid, ucinoleic acid, riachidonic acid, glycerol esters of the foregoing acids, or glycerol behenate.

The hydrophobic material preferably has a melting point of from about 40 to about 150°C., and is most preferably glyceryl behenate (e.g. Compritol™ from Gattefosse Inc., France). The surfactant is preferably selected from the group consisting of polyglycolized glycerides, polyoxyethylene sorbates, ethylene or propylene block copolymers or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate or Labrasol®, a polyglycolized glyceride (Gattefosse, France). The beadlet can further include sodium C₉-C₃₀ alkyl sulfate or citric acid. The beadlet can also contain a glidant (such as fumed silicon dioxide) to improve tabletting properties. Typically preferred therapeutic agents include acyclovir, acyclovir and at least one additional antiviral agent, dihydroergotamine or methylphenidate.

In another preferred embodiment the beadlets are coated with an immediate release coating, such as Opadry®I (hydropropylmethylcellulose, *i.e.*, HPMC) and Opadry®-II (HPMC, maltodextrin and propylene glycol) from Colorcon, Inc. (West Point, PA) or Aquateric® (cellulose acetate phthalate enteric polymer) from FMC, Inc. (Philadelphia, PA).

Another embodiment provides pharmaceutical compositions of a plurality of coated or uncoated single phase solid solution beadlets in a pharmaceutically acceptable carrier. The composition can be, for example, in the form of a tablet (optionally coated, such as with an enteric coating), buccal tablet, sublingual tablet, capsule or other oral dose delivery forms.

The oral delivery form can also be coated, if desired, with various protective

coating materials or with materials that control the rate or location of release in the patient. This can be done by known methods using such known materials.

Brief Description of the Drawings

Figure 1 is a plot of acyclovir transport through a Caco-2 cell monolayer using several of the Formulations described in Example 1.

Figure 2 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from Example 1. It illustrates the immediate release of acyclovir dissolved (%) over time from beadlets containing high percentages of glyceryl behenate and Labrasol®.

Figure 3 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from Example 1. It illustrates the effect of different methods of preparing acyclovir-beadlets, *i.e.* spray-melt and spray congealing on acyclovir release.

Figure 4 is a plot of acyclovir transport through a Caco-2 cell monolayer using Formulations of Example 2. Spray congealed acyclovir-containing beadlets are compared with control and placebo.

Figure 5 is a plot of acyclovir transport through a Caco-2 cell monolayer using Formulations of Example 2. Peptiscreen® results of acyclovir from beadlets made by a variety of processes are presented. Beadlets of Formulation PD0030-40 has an optional coating applied.

Figure 6 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from Example 2. It illustrates dissolution results from coated acyclovir beadlets (Formulation PD0030-40) made by a hot melt granulation process and uncoated acyclovir beadlets (Formulation PD0030-49) made by a spray congealing method.

Figure 7 is a plot of acyclovir-containing beadlet percent dissolution over time

for two of the Formulations from Example 2. It illustrates dissolution results from acyclovir beadlets made by a spray melt process (Formulation PD0030-52) and a hot melt process (Formulation PD0030-54). Both procedures give immediate release beadlets containing 48% glyceryl behenate.

Figure 8 is a plot of acyclovir-containing beadlet percent dissolution over time for one of the Formulations of Example 3.

Figure 9 is a plot of acyclovir transport through a Caco-2 cell monolayer using several of the Formulations described in Example 3. Peptiscreen® results of acyclovir transport from beadlets made by either spray congealing or hot melt granulation containing an anti-attacking agent are presented. Coated and uncoated beadlets are compared to the control.

Figure 10 is a plot of acyclovir-containing beadlet percent dissolutions over time for two of the Formulations from Example 3. It illustrates dissolution of acyclovir-containing hot melt beadlets, comparing Opadry coated beadlets with uncoated beadlets.

Figure 11 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 4. It illustrates dissolution results from acyclovir tablets containing coated beadlets made by the hot melt granulation process.

Figure 12 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 4. It illustrates the difference between tablets that contain Ac-Di-Sol® (Formulation PD0029-41B) and those that do not contain Ac-Di-Sol® (Formulation PD0029-41C) a rapid disintegrant.

Figure 13 is a plot of acyclovir transport through a Caco-2 cell monolayer using several formulations from Example 4. Peptiscreen® results of acyclovir transport from beadlets made by hot-melt granulation containing various percentages of Compritol 888 ATO and acyclovir are presented.

Figure 14 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 5. These are 100 mg acyclovir tablets containing Labrasol® beadlets with an Opadry® coating.

Figure 15 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 5 containing different tabletting excipients.

Figure 16 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 5. It illustrates the effect of different tabletting excipients on dissolution of acyclovir tablets containing coated beadlets.

Figure 17 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 5. It illustrates dissolution results from 100 mg acyclovir tablets containing coated beadlets blended with various tabletting lubricants.

Figure 18 is a plot of acyclovir-containing tablet percent dissolution over time for the Formulation PD0033-55 from Example 6.

Figure 19 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from Example 7.

Figure 20 shows drug transport across Caco-2 cells from acyclovir beadlet formulation shown in Example 8. The beadlets were prepared by a spray-congealed method.

Detailed Description of the Preferred Embodiments

The delivery system of the invention can be used to provide rapid controlled release of any of a broad variety of therapeutically active agents. Examples include the following: cough suppressants, such as dextromethorphan hydrobromide and codeine; antibiotics such as cephalosporin; antihistamines such as chlorpheniramine maleate, brompheniramine maleate, loratadine, astemizole, diclofenac sodium and terfenadine; decongestants such as pseudoephedrine and phenylephrine; antihypertensives such as

ACE-inhibitors, verapamil, nifedipine, propanolol, metoprolol, metoprolol succinate, metoprolol fumarate, metoprolol, methylphenadate, tartarate; agents to treat attention deficit disorder/hyperactivity such as methylphenadate, d and/or l isomers of methylphenadate, amphetamines, d and/or l isomers of amphetamines, and combinations of amphetamines; calcium channel blockers such as verapamil, diltiazam, nifedipine, nimodipine, felodipine, nicardipine, isradipine and amlodipine; antidiabetic agents such as glipizide and ibromectin; proton pump inhibitors such as omeprazole; anti-convulsants and anti-epileptics such as valproate sodium, clonazepam, gabapentin, and topiramate; anti-depressives such as buspirone, fluoxetine, 5-hydroxytryptamine receptor agonist and antagonist; anti-migraines such as sumatreptan and dihydroergotamine; antipsychotics such as resperidone; antiemetics such as ondansetron; anti-heartburns such as cisapride; H2 receptor antagonists such as cimetidine, ranitidine, famotidine, nizatidine; carbamazepine; beta adrenergic receptor blockers; anti-Parkinson agents such as selegiline, carbidopa/levodopa, pergolide, bromocriptine, amantadine, trihexyphenidyl HC1; antiviral agents including antiherpesvirus agents such as acyclovir, famciclovir, valcyclovir, foscarnet, ganciclovir; antiretroviral agents such as didanosine, stavudine, zalcitabine, zidovudine; and others such as amantadine, interferon alpha, ribavirin, rimantadine; anti Alzheimer's agents such as galantamine; and other therapeutic agents such as cimetidine, propiomazine, phenytoin, tacrine, propiazam, proplazam; vinca alkaloid.

Also contemplated are other therapeutic polypeptides and proteins, including fragments, analogs and mimetics thereof, and prodrugs which possess the same therapeutic activity, to at least a therapeutically useful extent, such as vasopressin, desmopressin, LHRH, luprolide, buserelin, calcitonin, insulin, parathyroid hormone, growth hormone(s) and erythropoietin. Further, examples include cyclosporin, angiotensin I, II and III, encephalins, enkephalins and their analogs, ACTH, antiinflammatory peptides I, II, III, bradykinin, cholecystikinin (CCK) fragments 26-33 and 30-33, pre/pro CCK (V-9-M), β -endorphin, dinorphin, leucokinin, leutinizing hormone releasing hormone (LHRH), neurokinins (e.g., neurokinin A), somatostatin, substance P, thyroid releasing hormone (TRH), vasopressin, fibrinogen receptor antagonists (arginine-glycine-aspartic acid containing peptides) which are platelet aggregation antagonists or inhibitors, growth hormone releasing peptides (GHRP),

insulin, LH-RH releasers and inhibitors, endothelins, glutamate or kainic acid neuro-excitation or neuro-toxicity inhibitors, GPIIb/IIIa receptor blockers such as the prodrug orbofiban, atrial natriuretic factor, gastrin, cytoprotectives, MSH modulators, or elastase or growth factors and cytokines, renin inhibitors, and HIV protease inhibitors.

Therapeutic agents can also include immunoactive agents selected from peptides, proteins, glycopolysaccharides and glycoproteins and fragments and analogs thereof, which possess the ability to suppress or eliminate immune responses thereto. Active analogs include compounds which have at least 90% structural homology to the proteins or to the active fragments. As such, the term includes, without limitations, any combination of their polypeptide domains or fragments possessing the ability to eliminate or suppress immune responses to the protein upon oral administration such as is used for replacement therapy. Examples of polypeptides include hormones, such as insulin; polypeptides to supplement a deficiency in production of a physiologically important polypeptide, such as hematologic regulatory factor; or cell or tissue preparations such as allogeneic or xenogeneic tissue or cells.

Therapeutic agents can also include immunoactive agents that can suppress or eliminate an immune response against allergens, particularly in cases of hypersensitivity caused by allergens, e.g. Type IV cell-mediated (delayed type) hypersensitivity. Also included are vaccines, especially those yielding mucosal immunity.

Therapeutic agents can also include those intended to be locally active in the gastrointestinal tract, such as therapeutics intended to treat Inflammatory Bowel Disease or Krohn's Disease, including corticosteroids such as beclomethasone dipropionate, budesonide, flunisolide, cromolyn, and nedocromil sodium.

Several methods are known in the art for the formation of beadlet/granule particles, both in uncoated and coated forms. The experiments reported in the Examples set forth below were performed using three of these methods: (i) a spray congealing method; (ii) a hot-melt method; and (iii) a spray-melt method. Each can be scaled in accordance with the stage of development.

The spray-congealing method begins with melting a typical pharmaceutically acceptable long chain alkyl-based wax that has a melting point of greater than or equal to about 55°C. Examples include stearic acid wax, glyceryl fatty acid esters (e.g. Compritol® brand), glyceryl monostearate or lauric acid wax. The melted wax is then mixed in a suitable mixing vessel, with the active pharmaceutical agent (usually 50-100 microns) and all other components of the beadlet composition, except for flow aids as described below. The mixture is sprayed into a spray-congeal tower or fluid bed processor. A flow of cool air is passed through the tower to solidify the beadlets. After the solidified beadlet has been formed, flow aids are added to prevent beadlet sticking, i.e. to make the beadlet surfaces more slippery, resulting in finished uncoated beadlets prepared by this method.

The hot-melt method is performed in a fluid bed, which takes the form of a vertical cylinder resting in a bowl-shaped base (one such device used in the Examples is the Wurster inserted in a Glatt GPCG5 fluid bed). The side walls of the cylinders have a number of spray nozzle entry ports along their length. A dry powder particulate mixture of the beadlet components, except for the wax and lubricant(s), is placed in the bowl and a metered flow of air is introduced into the cylinder. This raises the powder particles into the cylinder forcing a controlled flow pattern of the powder particles within at least one portion of the height of the cylinder. Then, melted wax and lubricant are introduced through some of these same nozzles, particularly the upper nozzles in an embodiment called the "top spray" method. The lower nozzles continue to introduce cool air from below to effect solidification of beadlets containing the powder, wax and lubricant components. The "top spray" method is used in several of the Examples presented herein.

The spray-melt method is also performed in a fluid bed. Solid ingredients (including wax that is solid at room temperature) i.e. not including liquid surfactants or solubilizing agents, are placed in a suitably configured fluid bed. Liquid surfactants, mixtures thereof and/or solubilizing agents are then sprayed onto the solid ingredients already in the fluid bed. This results in particles which are actually separate but attached drug, wax and surfactant components. These separate-component particles are

heated sufficiently to soften the wax, resulting in homogeneous particles which are then cooled to result in solidified beadlets. Several formulations in the Examples were prepared this way.

The composition or preparation of the invention can further include a surfactant, or a mixture of two or more surfactants. A surfactant is an amphiphilic molecule consisting of a hydrophobic tail and a hydrophilic head. These molecules possess distinct regions of both hydrophilic and hydrophobic character. The hydrophobic tail can be a hydrocarbon or fluorocarbon chain of 8 to 18 carbon atoms. They are long chain molecules such as, for example, soaps or detergents. Surfactants accumulate at the hydrophilic/ hydrophobic (water/oil) interface and lower the surface tension at the interface. One effect of a reduced surface tension is the stabilization of the emulsions. This is because molecules with both polar and non-polar groups become oriented such that the hydrocarbon tail embeds itself into the hydrophobic phase and the hydrophilic head protrudes into the hydrophilic phase. Where the hydrophobic composition or other component of the preparation includes a surface-active agent, such as a surfactant, it is usually present in amounts of about 3% to 50.0% weight/weight of the beadlet or granule composition with a preferred range of 3% to 10% (w/w). Preferred surfactants include, for example, the Tween (polyoxyethylene sorbate) family of surfactants (ICI, Wilmington, DE), the Span (sorbitan long chain carboxylic acid esters) family of surfactants (ICI), the Pluronic (ethylene or propylene oxide block copolymers) family of surfactants (BASF, Parsippany, NJ), the Labrasol, Labrafil and Labrafac (each polyglycolized glycerides) families of surfactants (GatteFossé, St. Priest, France), sorbitan esters of oleate, stearate, laurate or other long chain carboxylic acids, poloxamers (polyethylene-polypropylene glycol block copolymers), other sorbitan or sucrose long chain carboxylic acid esters, mono and diglycerides, PEG derivatives of caprylic/capric acid triglycerides and mixtures thereof.

Coating of the beadlets formed by any of the above methods is achieved as follows. Representative preferred surfactants are polymer 124, a poly-glycolized glyceride, sorbitan laurate, polyoxyethylene (20) sorbitan monooleate. An aqueous solution of an "immediate release" coating is formed and sprayed onto the beadlets substantially immediately after they have been formed, using the same apparatus and

same nozzles by which the beadlets were formed. A list (non-limiting) of release coating materials and suppliers is provided in Table 1 below. At this point, more flow aid may be introduced briefly. The beadlets are then discharged to a blender (such as a Patterson-Kelly V-blender).

Major fluid bed processors and suppliers include Aeromatic and Multiprocessor series (Niro Inc., Columbia, MD 21045); GPCG series (Glatt Air Techniques, Inc., Ramsey, NJ 07446); Vector fluid bed series (Vector Corporation, Marion, IA 52302); and Kugel Coater series (Huttl, Coating-Technik GmbH, Steinen, Germany).

Table 1
Major Immediate Release Coating Material and Suppliers

<u>Brand name</u>	<u>Ingredients</u>	<u>Manufacturer</u>
Opadry®I	HPMC, PEG & pigment	Colorcon, West Point, PA
Opadry II®	HPMC, PEG, maltodextrin & pigment	Colorcon, West Point, PA
Klucel	Hydroxypropyl cellulose	Hercules/Aqualon, Wilmington, DE
Natrosol	Hydroxyethyl cellulose	Hercules/Aqualon, Wilmington, DE
Kollidon	Polyvinyl pyrrolidone	BASF, Parsippany, NJ
Kelton	Sodium alginate	Kelco, San Diego, CA 92123
Pharmaceutical gelatin	Gelatin	Hormel Foods Corp., Austin, MN

The beadlets can be incorporated into hard gelatin capsules, either with additional excipients, or alone. Typical excipients to be added to a capsule formulation include, but are not limited to: fillers such as microcrystalline cellulose, soy polysaccharides, calcium phosphate dihydrate, calcium sulfate, lactose, sucrose,

sorbitol, or any other inert filler. In addition, there can be flow aids such as fumed silicon dioxide, silica gel, magnesium stearate, calcium stearate or any other material imparting flow to powders. Because of their hydrophobic nature, the particles should not need a lubricant, but one can be added if necessary by using polyethylene glycol, leucine, glycetyl behenate, magnesium stearate or calcium stearate.

The beadlets can also be incorporated into a tablet, in particular by incorporation into a tablet matrix, which rapidly disperses the particles after ingestion. In order to incorporate these particles into such a tablet, a filler/binder must be added to a tablet that can accept the particles, but will not allow their destruction during the tableting process. Materials that are suitable for this purpose include, but are not limited to, microcrystalline cellulose (Avicel), soy polysaccharide (Emcosoy), pregelatinized starches (STARCH 1500, National 1551), and polyethylene glycols (Carbowax). The materials should be present in the range of 5-75% (w/w), with a preferred range of 25-50% (w/w).

In addition, disintegrants are added in order to disperse the particles once the tablet is ingested. Suitable disintegrants include, but are not limited to: cross-linked sodium carboxymethyl cellulose (Ac-Di-Sol), sodium starch glycolate (Explotab, Primojel), and cross-linked polyvinylpolypyrrolidone (Plasdone-XL). These materials should be present in the range of 3-15% (w/w), with a preferred range of 5-10% (w/w).

Lubricants are also added to assure proper tableting, and these can include, but are not limited to: magnesium stearate, calcium stearate, stearic acid, polyethylene glycol, leucine, glycetyl behanate, and hydrogenated vegetable oil. These lubricants should be present in amounts from 0.1-10% (w/w), with a preferred range of 0.3-3.0% (w/w).

Tablets are formed, for example, as follows. The particles are introduced into a blender along with Avicel, disintegrants and lubricant, mixed for a set number of minutes to provide a homogeneous blend which is then put in the hopper of a tablet press with which tablets are compressed. The compression force used is adequate to form a tablet; however, not sufficient to fracture the beads or coatings.

The tablets can also be coated with conventional coatings known for a variety of effects, *e.g.* enteric, immediate or sustained release.

Caco-2 Cell Monolayer Testing of Drug Transport

We have used a cell culture based model to test formulations to improve intestinal adsorption of poorly adsorbed drugs. This allows testing of transport through intestinal epithelium without the influence of gastric hydrolysis or enzyme degradation in the GI tract, blood, or liver. It further allows simultaneous testing of multiple different formulations.

The Caco-2 cell line is derived from human colon cancer cells. They are epithelial-type cells that differentiate, in culture, into cell monolayers that are extremely similar to normal fetal intestinal epithelium. Intestinal epithelium is the cell type that lines the intestine. It has very specific adsorptive and barrier properties to allow absorption of nutrients but prevent passage of most of the intestinal contents. Two important characteristics of intestinal epithelium are the brush border, which forms the luminal surface of the epithelium, and the tight junctions, which are impenetrable fusions between cells. The brush border is important because it produces the enzymes and specialized membrane structures that allow cells to selectively absorb important nutrients such as glucose; tight junctions are important because they form continuous connection between cells and allow the epithelium to exclude unwanted molecules. Caco-2 cells, as used in our assays, display both of these characteristics.

Caco-2 colon carcinoma cells were obtained from the American Tissue Culture Collection (Rockville, MD) and maintained in culture in high glucose DMEM with 10% fetal calf serum, plus pen/strep, at 37°C, in 5% CO₂. Cells are subcultured roughly every 5-7 days, 1:3 in T75 flasks, or when cells are 80-90% confluent, as determined by visual inspection. Caco-2 cells are adherent and are disassociated from the surface of the flask by incubation at room temperature with 0.25% trypsin in Hank's balanced salt solution (HBSS) without calcium or magnesium. Caco-2 cells are contact inhibited and when they become confluent, begin to differentiate and lose the capacity to undergo mitosis. To maintain a consistent genotype, it is important to avoid selecting for a subset of cells that is not differentiated. This is done by subculturing working stocks of cells before they differentiate. Initial experiments establish the time course of differentiation.

Transport studies use differentiated cells, which are cells that have acquired many of the characteristics of normal intestinal epithelium including a brush border and barrier properties. Transport experiments use 2.45 cm Transwell cell culture inserts with 3.0 μ m pores (Costar, Boston, MA). These are plastic inserts for tissue culture wells, which allow a distinct apical and basal compartment only connected by small pores on the growing surface. Cells are seeded on the upper surface of the insert at 3×10^5 cells per well and media changed every day. Media was changed in the lower compartments by lifting insert with a sterile forceps. The upper compartment holds 1.5 ml, and the lower 2.6 ml. Tissue culture reagents can be purchased from GIBCO-Life Technologies (Gaithersburg, MD) or Biofluids (Rockville, MD).

Transport studies usually include polyethylene glycol (PEG) 4000 as a large, nonreactive, reference molecule, which would not permeate normal epithelium, and the following test peptides, which have a range of molecular weights and hydrophilicity: thyrotrophin releasing hormone (TRH) (MW=362.15), DAGO-enkephalin (MW=513.26) and [ARG8-] vasopressin (MW=1083.41). Glucose transport is also measured using 3 H and 14 C labeled D- and L- glucose. Unlabeled peptides can be purchased from Peninsula Laboratories, Belmont, CA. Tritium-labeled peptides and glucose and 14 C-PEG can be purchased from NEN-DuPont, Boston, MA, or Amersham Corp., Arlington Heights, IL.

For transport determinations unlabeled peptides, concentration 10 mM, and labeled, concentration of 1 μ Ci per ml and transport enhancers, are added to HBSS plus calcium and magnesium. Transport media, containing peptide or glucose plus labeled and unlabeled PEG, is added to the upper compartment of the Transwell, where the test solution is in contact with the apical surface of the cells. Transport is measured by taking aliquots from the lower compartment, which is in contact with the basal surface of the cells. Studies are performed in a six-well tissue culture plate and Transwells are moved to a new well every twenty minutes, giving determinations for two hours. An aliquot of media is removed from the upper and lower compartments, scintillation cocktail is added (NEN DuPont) and the total radioactivity from the upper and lower compartments is calculated. Transport is calculated as percent transport per hour from top to bottom. Because in all experiments the amount of peptide in the upper compartment is large compared to the amount transported, no correction is made for loss of peptide in the upper compartment with time. Radioactivity is measured in a Wallac or Beckman scintillation counter.

The following examples further illustrate the invention but are not limitations of its scope.

Example 1Uncoated Single Phase Solid Solution Beadlets

Uncoated beadlets were prepared, as described above and in Table 2, to have the formulations set forth in Table 2.

Table 2
Uncoated Beadlet Formulations

Formulation	PD0030-01	PD0030-05	PD0030-08	PD0030-11
Core Formulation				
Acyclovir USP 30µm	35	25	35	-
Acyclovir-micronized	-	-	-	35
Labrasol	20	20	20	20
Compritol 888 ATO	40	55	40	40
Talc	5	0	5	5
Total	100	100	100	100
Core Preparation	Spray-melt	Spray-cong	Hot-melt	Spray-melt
Form	Granules	Beadlets	Granules	Granules
Size	~300 µm	<100 µm	~250 µm	~200 µm

Table 2 demonstrates that acyclovir beadlets can be prepared by a variety of methods. Acyclovir, USP or micronized acyclovir can be used. The particle size of original drug does not affect the beadlet formation.

Table 3
Additional Uncoated Beadlet Formulations

Formulation	PD0030-14	PD0030-17	PD0030-20	PD0030-23
Core Formulation				
Acyclovir USP	-	35	-	-
Acyclovir-micronized	35	-	35	35
Labrasol	20	20	25	25
Compritol 888 ATO	40	42	37	33
SLS	-	1	1	1
Citric Acid	-	1	1	1
Talc	5	1	-	5
Cab-O-Sil	-	-	1	-
Total	100	100	100	100
Core Preparation	Hot-melt	Spray-cong	Spray-melt	Spray-melt
Form	Granules	Beadlets	Granules	Granules
Size (estimated)	~200 µm	<100 µm	large	large

When increasing amounts of Labrasol go to 25%, the beadlet size is increased and the process has to be optimized to obtain desired beadlet size. The addition of 5% talc does not change the particle size of beadlets significantly.

Table 4
Acyclovir Transport Through Caco-2 Cell Monolayers

Formulation	Initial Conc.(mg/ml)	Transport μg/ml/hr	Transport sample/control ratio
CONTROL	46.6	40	1.0
PD0030-01	46.6	718	18.0
PD0030-05	33.3	731	18.3
PD0030-08	46.6	751	18.8
PD0030-11	46.6	648	16.3
PD0030-14	33.3	686	17.2
PD0030-17	46.6	746	18.7
PD0030-20	46.6	827	20.7
PD0030-23	33.3	701	17.6

Beadlets having these Formulations were tested for drug transport in the Caco-2 cell monolayer model described above. The results are reported in Table 4 and also in Figure 1.

Figure 2 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from this Example (PD0030-01A and PD0030-01D). It illustrates the immediate release acyclovir dissolved (%) over time from beadlets containing high percentages of glyceryl behenate and Labrasol®.

Figure 3 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from this Example (PD0030-11 and PD0030-17). It illustrates the effect of different methods of preparing acyclovir-beadlets, *i.e.* spray-melt and spray congealing on acyclovir release.

Example 2Coated and Uncoated Beadlet Formulations

Additional Formulations for coated and uncoated beadlets are provided in this Example. Preparation was as described above and in Tables 5 and 6.

Table 5
Coated And Uncoated Beadlet Formulations

Formulation	PD0030-40A	PD0030-45	PD0030-47	PD0030-49
Core Formulation	PD0030-14			
Acyclovir (30 µm)			25	
Acyclovir (16 µm)		35		25
Labrasol		20	20	20
Tween 20				
Compritol 888 ATO		40	55	54
SLS				
Citric Acid				1
Talc		5		
Total		100	100	100
Core Preparation	Hot-melt	Spray-melt Top spray	Spray-congeal	Spray-congeal
			Size>100µm	Top Spray
Blend pre-coat		10% Talc	10% HPMCAS*	
Coating Method	Wurster	Wurster	Wurster	
Coating polymer	8% Opadry	20% 4110D**	20% L30D	
Coating level	5%	<2%	10%	

* HPMCAS = hydroxypropylmethylcellulose acetate succinate

** Eudragit 411 OD, a new enteric polymer

Table 6
Additional Coated Beadlet Formulations

Formulation	PD0030-52	PD0030-54	PD0030-55	PD0030-61	PD0030-63
Core Formulation			PD0030-47		
Acyclovir (Avg 30 μ m)				35	0
Acyclovir (Avg: 16 μ m)	30	30			
Labrasol	20	20		20	20
Compritol 888 ATO	48	48		40	58
SLS	1	1			1
Citric Acid	1	1			1
Talc	-	-		5	20
Total	100	100		100	100
Core Preparation	Spray-melt	Hot-melt		Spray-melt	Hot-melt
	Wurster	Wurster			Size<100 μ
Blend pre-coat			10% HPMCAS		
Coating Method			Wurster	Wurster	
Coating polymer			20% L30D	20% L 30D	
Coating level			50%	<2%	

PD0030-52 and PD0030-54 illustrate beadlets made in a fluid bed processor with a Wurster inserter, used for either a spray-melt or a hot-melt granulation method. PD0030-47 and PD0030-55 illustrate that spray-congealed beadlets can be coated with an enteric polymer (Eudragit L30D) at a 10% coating level and a 50% coating level, respectively. PD0030-63 is a placebo formulation.

Beadlets having Formulations reported in this Example were tested for drug transport in the Caco-2 cell monolayer model described above. The results are reported in Table 7 and also in Figures 4 and 5.

Table 7
Acyclovir Transport Through Caco-2 Cell Monolayer

Formulation	Initial Conc. (mg/ml)	Transport $\mu\text{g}/\text{ml}/\text{hr}$	Transport sample/control ratio
CONTROL	33.3	44.2	1.0
PD0030-49	33.3	735	16.6
PD0030-54	40.0	631	14.3
PD0030-63	00.0	0.319	0.0072
CONTROL	33.3	37.2	1.0
PD0030-40A	40.0	584	15.7
PD0030-52	40.0	624	16.8
PD0030-54	40.0	599	16.1
PD0030-55	24.0	214	5.8

Figure 4 is a plot of acyclovir transport through a Caco-2 cell monolayer using Formulations of this Example. Spray congealed acyclovir-containing beadlets are compared with control and placebo.

Figure 5 is a plot of acyclovir transport through a Caco-2 cell monolayer using

Formulations of this Example. Peptiscreen® results of acyclovir from beadlets made by a variety of processes are presented. Beadlets of Formulation PD0030-40 have an optional coating applied.

Figure 6 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from this Example. It illustrates dissolution results from coated acyclovir beadlets (Formulation PD0030-40) made by a hot melt granulation process and uncoated acyclovir beadlets (Formulation PD0030-49) made by a spray congealing method.

Figure 7 is a plot of acyclovir-containing beadlet percent dissolution over time for two of the Formulations from this Example. It illustrates dissolution results from acyclovir beadlets made by a spray melt process (Formulation PD0030-52) and a hot melt process (Formulation PD0030-54). Both procedures give immediate release beadlets containing 48% glyceryl behenate.

Example 3Varied Manufacturing Procedures Give Uniform Transport Results

Table 8
Beadlet Formulations

Formulation	PD0030-69	PD0030-71	PD0030-73	PD0030-75
Core Formulation				
Acyclovir (Avg: 16 μ m)	30	30	30	30
Labrasol	20	20	20	20
Compritol 888 ATO	43	43	43	43
SLS	1	1	1	1
Citric Acid	1	1	1	1
Talc	5	5	5	5
Total	100	100	100	100
Core Preparation	Hot-melt	Hot-melt	Hot-melt	Hot-melt
Product Temp. °C	Low	Low	High	Low
Spray rate, g/min	High	Low	Low	Low
Melt and air temp., °C	High	Low	High	High

Figure 8 is a plot of acyclovir-containing beadlet percent dissolution over time for one of the Formulations of this Example (Formulation PD0030-69).

Table 9
Beadlet Formulations

Formulation	PD0030-77	PD0030-79	PD0030-81	PD0030-83
Core Ingredients				
Acyclovir (Avg: 16 µm)	30	30	30	30
Labrasol	20	20	20	20
Compritol 888 ATO	43	43	43	43
SLS	1	1	1	1
Citric Acid	1	1	1	1
Talc	5	5	5	5
Total	100	100	100	100
Core Preparation	Hot-melt	Hot-melt	Hot-melt	Hot-melt
Product Temp., °C	High	Low	High	High
Spray rate, g/min	High	High	Low	High
Melt and air temp. °C	High	Low	Low	Low

Table 10
Acyclovir Formulations

Formulation	PD0030-85	PD0030-88	PD0030-90
Core Ingredients			PD0030-31
Acyclovir (Avg: 16 μm)	30	-	30
Acyclovir (Avg: 30 μm)	-	25	-
Labrasol	-	-	20
Tween 20	20	20	-
Compritol 888 ATO	43	53	43
SLS	1	1	1
Citric Acid	1	1	1
Talc	5		5
Total	100	100	100
Core Preparation	Hot-melt	Spray congeal	Hot-melt
	Size<100 μm	Beadlet <100 μm	
Coating Method			Top
Coating polymer			10% Opadry
Coating level			10%

PD0030-90 illustrates that beadlets can be coated with a Opadry® polymer solution using a conventional fluid bed processor.

Table 11
Beadlet Formulations

Formulation	PD0030-98	PD0033-04
Core Formulation	PD0030-85	PD0030-88
Core Preparation	Hot-melt	Spray- congeal
Coating Method	Wurster	Wurster
Coating polymer	10% Opadry	8% Opadry
Coating level	20%	20%

Table 11 shows that Acyclovir beadlets can be coated with opadry polymer individually, regardless of preparation methods, *e.g.*, hot-melt or spray-congealing.

Beadlets having Formulations reported in this Example were tested for drug transport in the Caco-2 cell monolayer model described above. The results are reported in Table 12 and also in Figure 9.

Table 12
Acyclovir Transport Through Caco-2 Cell Monolayers

Formulation	Initial Conc. (mg/ml)	Transport ug/ml/hr	Transport sample/control ratio
Control	33.3	27.7	1.0
PD0030-69	40.0	989	35.7
PD0030-71	40.0	1050	38.0
PD0030-85	40.0	1138	41.1
PD0030-88	33.3	1184	42.8
PD0030-90	13.3	1016	36.7
PD0030-98	26.7	1007	36.4
PD0033-04	20.0	1063	38.4

Figure 9 is a plot of acyclovir transport through a Caco-2 cell monolayer using several of the Formulations described in this Example. Peptiscreen® results of acyclovir transport from beadlets made by either spray congealing or hot melt granulation containing an anti-attacking agent are presented. Coated and uncoated beadlets are compared to the control.

Figure 10 is a plot of acyclovir-containing beadlet percent dissolutions over time for two of the Formulations from this Example. It illustrates dissolution of acyclovir-containing hot melt beadlets, comparing Opadry® coated beadlets with uncoated beadlets.

Example 4Tablets Formed Using Various Beadlet FormulationsTable 13Tablet Formulations

Formulation	PD0029-39	PD0029-40	PD0029-41A	PD0029-41B
Tablet Formulation				
Acyclovir Granules	50	50	50	50
Core Formulation	PD0030-85	PD0030-90	PD0030-90	PD0030-90
Avicel PH302	38	38	43	46
Ac-Di-Sol	10	10	5	2
Cab-O-Sil	1	1	1	1
SLS	1	1	1	1
Note	Stokes	Stokes	Stokes	Stokes
Tablet wt., mg	400	440	440	440
Shape	round	round	round	round
Hardness, Kp	N/A	5	5	6

Table 14
Tablet Formulations

Formulation	PD0029-41C	PD0029-43A	PD0029-43B	PD0029-43C
Tablet Formulation				
Acyclovir Granules	50	50	60	70
Core Formulation	PD0030-90	PD0030-90	PD0030-90	PD0030-90
Avicel PH302	48	45	35	25
Lactose 316	-	-	-	8
Ac-Di-Sol	-	3	3	3
Cab-O-Sil	1	1	1	1
SLS	1	-	-	-
Mg Stearate	-	1	1	1
Note	Stokes	Stokes	Stokes	Stokes
Tablet wt., mg	440	400	400	400
Shape	round	round	round	round
Hardness, Kp	6-6.5	5	5	5

These tablets were made to demonstrate that beadlet tablets could be made with water soluble lubricants (Formulations PD0029-39 and PD0029-40) and to study the effect of a disintegration agent on drug release from tablets (Formulations PD0029-40 and PD0029-41AC). Also, the amount of acyclovir granules was varied to examine the effect on drug release from the tablets.

Table 15
Beadlet Tablet Formulations

Formulation	PD0029-44A	PD0029-44B	PD0029-45A	PD0029-45B	PD0029-45C
Tablet Formulation					
Acyclovir Granules	60	60	60	60	60
Core Formulation	PD0030-90	PD0030-90	PD0030-90	PD0030-90	PD0030-90
Avicel PH302 ATO	36	34	30	25	20
Starch 1500	0	0	5	10	15
Ac-Di-Sol	3	3	3	3	3
Cab-O-Sil	1	1	1	1	1
Mg Stearate	0	2	1	1	1
Note	Stokes	Stokes	Stokes	Stokes	Stokes
Tablet wt., mg	400	400	430	430	430
Shape	round	round	round	round	round
Hardness, Kp	N/A	5	6	5	4.6

Formulations PD0029-44A and -44B illustrate the addition of lubricant to tablet preparations. The tablets were studied for the effect of this on drug release.

Formulations PD0029-45A through -45C illustrate the addition of starch 1500 to tablet preparations. The tablets were studied for the effect of this on drug release.

Table 16
Beadlet Tablet Formulations

Formulation	PD0033-07A	PD0033-07B	PD0033-07C	PD0033-09A
Core Formulation				
Acyclovir, USP	61.0	54.3	50	61.0
Labrasol	7.6	9.1	10	11.4
Compritol 888 ATO	29.0	34.4	38	25.2
SLS	1.2	1.1	1	1.2
Citric Acid	1.2	1.1	1	1.2
Total	100	100	100	100
Granulation Method	Hot-melt	Hot-melt	Hot-melt	Hot-melt
Product Temp., °C	40	40	40	40
Spray rate, g/min	60	60	60	60
Melt and air temp., °C	120	120	120	120
Bulk density, g/ml			0.36	
Tap density, g/ml			0.57	
% larger than 140 mesh			6.1	
Ave. particle size, µm			<100 µm	

Table 17
Beadlet Tablet Formulations

Formulation	PD0033-09B	PD0033-09C	PD0033-11A	PD0033-11B	PD0033-11C
Core Formulation					
Acyclovir, USP	57.7	50	63.4	57.7	50
Labrasol	12.5	15	12.5	16.7	20
Compritol 888 ATO	27.5	33	17.5	23.3	28
SLS	1.15	1	1.3	1.15	1
Citric Acid	1.15	1	1.3	1.15	1
Total	100	100	100	100	100
Granulation Method					
Product Temp., °C	40	40	40	40	40
Spray rate, g/min	60	60	60	60	60
Melt and air temp., °C	120	120	120	120	120
Bulk density, g/ml		0.33			0.33
Tap density, g/ml		0.54			0.55
% larger than 140 mesh		16.2			26.2

In Tables 16 and 17, PD0033-07A through -07C, PD0033-09A through -09C and PD0033-11A through -11C were prepared to study the effect of transport enhancer on processing and drug transport a Caco 2 cell monolayer.

The Labrasol® content was also modified to cover the range from 7.6% to 20%.

Table 18
Beadlet Tablet Formulations

Formulation	PD0033-13A	PD0033-13B	PD0033-13C	PD0033-15
Core Formulation				PD0033-13C
Acyclovir, USP	61.0	54.3	50	
Tween 20	11.4	13.6	15	
Compritol 888 ATO	25.2	29.9	33	
SLS	1.2	1.1	1	
Citric Acid	1.2	1.1	1	
Total	100	100	100	
Granulation Method	Hot-melt	Hot-melt	Hot-melt	
Product Temp., °C	40	40	40	
Spray rate, g/min	60	60	60	
Melt & air temp., °C	120	120	120	
Coating method				Top spray
Coating polymer				15% Opadry-II
Coating level				10%
Note				1% Cabosil
Bulk density, g/ml			0.35	0.29
Tap density, g/ml			0.54	0.38

In Table 18, PD33-13A through -13C show different amounts of transport enhancers to study their effect on processing and drug transport.

Formulation PD0033-15 shows coating of a beadlet formed by hot-melt granulation with Opadry® II.

Table 19
Acyclovir Transport Through Caco-2 Cell Monolayers

Formulation	Initial Conc. (mg/ml)	Transport $\mu\text{g}/\text{ml}/\text{hr}$	Transport sample/control ratio
CONTROL	66.6	18.9	1.0
PD0033-07A	66.6	786	41.5
PD0033-07B	66.6	817	43.2
PD0033-07C	66.6	805	52.5
PD0033-09A	66.6	899	47.5
PD0033-09B	66.6	891	47.1
PD0033-09C	66.6	898	47.5
PD0033-11A	66.6	930	49.2
PD0033-11B	66.6	967	51.1
PD0033-11C	66.6	994	52.5
PD0033-13A	66.6	1127	59.6
PD0033-13B	66.6	1119	59.1
PD0033-13C	66.6	1056	55.8

Figure 11 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It illustrates dissolution results from acyclovir tablets containing coated beadlets made by the hot melt granulation process.

Figure 12 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It illustrates the difference between tablets that contain Ac-Di-Sol® (Formulation PD0029-41B) and those that do not contain Ac-Di-Sol® (Formulation PD0029-41C) a rapid disintegrant.

Beadlets having Formulations reported in this Example were tested for

drug transport in the Caco-2 cell monolayer model described above. Figure 13 is a plot of acyclovir transport through a Caco-2 cell monolayer using several formulations from this Example. Peptiscreen® results of acyclovir transport from beadlets made by hot-melt granulation containing various percentages of Compritol 888 ATO and acyclovir are presented. The data are in tabular form in Table 19.

Example 5
Table 20
Beadlet Tablet Formulations

Formulation	PD0029-54A	PD0029-54B	PD0029-54C	PD0029-55A
Tablet Formulation				
Acyclovir granules	50	50	50	50
Core Formulation	PD0033-07C	PD0033-09C	PD0033-13C	PD0033-13C
Avicel PH 302	24	24	24	36
Starch 1500	-	-	-	10
Calstar	14	14	14	-
AC-Di-Sol	2	2	2	2
Talc	5	5	5	
Cab-O-Sil	1	1	1	0.5
SLS	1	1	1	1
Na Stearyl Fumarate	3	3	3	-
Mg Stearate	-	-	-	0.5
Note	Stokes	Stokes	Stokes	Stokes
Tablet wt., mg	400	400	400	400
Shape	round	round	round	round
Hardness, Kp	5.5	5	5	5

Figure 14 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. These are 100 mg acyclovir tablets

containing Labrasol® beadlets with an Opadry® coating.

Figure 15 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example containing different tabletting excipients.

Table 21
Acyclovir Tablet Formulations

Formulation	PD0029-55B	PD0029-55C	PD0029-55D	PD0029-56A
				15% opadry
Tablet Formulation				
Acyclovir granules	50	50	50	50
Core Formulation	PD0033-13C	PD0033-17	PD0033-17	PD0033-17
Avicel PH 102		34	34	33
Starch 1500	10	10	10	10
AC-Di-Sol	2	2	2	2
Talc			4	
Cab-O-Sil	0.5	0.5	0.5	0.5
SLS	1	1	1	1
Na Stearoyl Fumarate	-	-	-	6
Mg Stearate	0.5	0.5	0.5	0.5
Myvaplex TL	-	2	-	3
Stearic Acid			2	
Note	Stokes	Stokes	Stokes	Stokes
Tablet wt., mg	400	400	400	400
Shape	round	round	round	round
Hardness, Kp	5	5.4	5.2	5

Figure 16 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It illustrates the effect of different tabletting

excipients on dissolution of acyclovir tablets containing coated beadlets. *See Tables 20 and 21.*

Figure 17 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It illustrates dissolution results from 100 mg acyclovir tablets containing coated beadlets blended with various tabletting lubricants. As much as 6% sodium stearoyl fumarate is used in Formulation PD0029-56A, with loss in immediate release properties. *See Table 21.*

Example 6Beadlet Coated Granulation FormulationsTable 22Beadlet Formulations

Formulation	PD0033-45	PD0033-55
		10% Opadry
Tablet Formulation		
Acyclovir granules	50	50
Core Formulation	PD0033-38	PD0033-40
Avicel PH 301	34	31
Lactose 316	10	10
Starch 1500		
Calstar		
AC-Di-Sol	2	2
Corn Starch		
Cab-O-Sil	0.5	0.5
SLS	1	1
Stearic acid	2	4
Mg Stearate	0.5	1.5
Note		Stokes
Tablet wt., mg	400	400
Shape	round	round
Hardness, Kp		6

Figure 18 is a plot of acyclovir-containing tablet percent dissolution over time for the Formulation PD0033-55 from this Example. It presents dissolution results from 100 mg acyclovir tablets containing coated beadlets. The coated beadlets contain 60% acyclovir and are Tween 20 based.

Example 7Table 23Formulations of Acyclovir Enteric Coated Tablets

Formulation	PD0033-67B	PD0030-67C
Acyclovir, USP	25.110	25.110
compritol 888 ATO, NF	11.300	11.300
Labrasol, EP	4.185	--
Tween 20, USP	--	4.185
SLS, NF/USP	1.348	1.348
Citric Acid, Anhydrous, USP	0.419	0.419
Cab-O-Sil M5, NF	0.884	0.884
Opadry II, Clear, NF	4.650	4.650
Avicel PH301, NF	31.62	28.83
Lactose 316, NF/USP	9.300	9.300
Ac-Di-Sol, USP	1.860	1.860
Stearic Acid, USP	1.860	3.720
Mg Stearate	0.465	1.395
Eudragit L30D-55, NF	4.375	4.375
Triethyl Citrate, NF	0.437	0.437
Talc, USP	2.188	2.188
Total	100.00	100.00

Figure 19 is a plot of acyclovir-containing tablet percent dissolution over time for two of the Formulations from this Example. It presents dissolution results for 150 mg enteric coated acyclovir tablets containing coated beadlets made using either Tween 20 to Labrasol® surfactants in combination with 27% Compritol 888 ATO.

Example 8

The acyclovir beadlets were prepared by a spray-congealed method. The stearic acid or

Myvaplex 600 was melted in a stainless steel vessel. The other ingredients, except acyclovir powder, were then added into the molten solution of the wax while stirring. Finally, acyclovir was dispersed into the above molten solution at the temperature above the melting point of the mixture. The molten dispersion was pumped to a portable spray-dryer unit and atomized by a dual-fluid nozzle. The congealed product was collected either on the bottom of the chamber or in the cyclone.

Table 24
Formulation Of Acyclovir Beadlets Prepared By a Spray-Congealed Method

Ingredient	PD0022-37	PD0022-38
Acyclovir	25	25
Stearic Acid		50
Myvaplex 600	50	
Labrasol	12	12
Labrafac CM10	3	3
Gelucire 50/13	10	10
TOTAL	100	100

Figure 20 shows levels of drug transport in the Caco-2 cell model of the above prepared beadlets. Both the PD0022-37 formulation with Myvaplex 600 and the PD0022-38 formulation continuing stearic acid provided enhanced drug transport levels over the control.

Example 9

Preparation of drug-containing granules for amphetamine base and salts, derivatives and their combinations.

The following formulation was used to prepare amphetamine granules. The drugs and other ingredients were charged into a fluid bed processor (GPCG-5, Glatt). The molten components (Myvaplex 600 and Tween 20) were sprayed onto the fluidized powder bed under suitable conditions. The resulting granules were then coated with Opadry II. The drug-loaded granules can be further coated with enteric polymers or sustained release polymers. The final dosage form for the granules can be a capsule or a tablet.

Table 25

Core Formulation	%
Amphetamine salts	15.00
Xylitol	28.00
Explotab	20.00
Citric Acid	5.00
Myvaplex 600	20.00
Tween 20	6.00
Opadry II	5.00
Cab-O-Sil	1.00
Total	100.00
Core Preparation	Hot-melt
Form	Granules
Size (estimated)	~400 μ m

Example 10Uncoated Single Phase Beadlets**Table 26**

Formulation	A	B	C	D
Calcitonin Sodium	0.2			
Beclomethasone Dipropionate		5		
Testosterone			2	
Alendronate Sodium				8
Lactose	29.8		46	21
Compritol 888 AOT	48	48	30	
Myvaplex 600		46	10	50
Tween 20	20			
Labrasol			10	20
SLS	1	1	1	1
Citric Acid	1			1
Total	100	100	100	100
Core Preparation	Spray-melt	Spray-cong	Hot-melt	Spray-melt
Form	Beadlets	Beadlets	Beadlets	Beadlets
Size (estimated)	Large	<100 um	Large	Large

Method of Preparation

Formulations A and D: The spray-melt method is performed in a fluid bed. Solid ingredients including the active ingredients, lactose Compritol 888 ATO, Myvaplex 600, SLS, and citric acid, are placed in a suitably configured fluid bed. Liquid surfactants, i.e., Tween 20 and Labrasol, are then sprayed onto the solid ingredients in the fluid bed to form granules. In the case of calcitonin sodium, lactose triturate is prepared to ensure content uniformity.

Formulation B: The waxy materials are melted in a suitable mixing vessel and all other ingredients are mixed in the melted wax. The mixture is sprayed into a spray-congealer or fluid bed processor to solidify the beadlets.

Formulation C: The hot-melt method is performed in a fluid bed. Solid ingredients including the active ingredient, lactose, SLS, and citric acid, are placed in a fluid bed. The melted waxes with liquid surfactant are then sprayed onto the solid ingredients in the fluid bed to form granules.

What Is Claimed Is:

1. A composition comprising:

at least one therapeutic agent and a solid beadlet comprising at least 20% by weight of at least one hydrophobic long chain fatty acid or ester thereof and at least 3.0% by weight of at least one surfactant, said therapeutic agent being dispersed in said beadlet.

2. The composition of Claim 1 wherein:

the surfactant is present in an amount from about 3.0% to about 40% by weight; and;

said at least one therapeutic agent is present in an amount from about 0.1% to about 70% by weight of at least one therapeutic agent which in combination form a solid solution at room temperature.

3. The composition of claim 1 wherein the hydrophobic material has a melting point of from about 40 to about 100 °C.

4. The composition of claim 1 wherein the hydrophobic material is glyceryl behenate.

5. The composition of claim 1 wherein the surfactant is selected from the group consisting of polyglycolized glycerides, polyoxyethylene sorbates, ethylene or propylene block copolymers or combinations thereof.

6. The composition of claim 5 wherein the surfactant is polyoxyethylene 20 sorbitan monolaurate.

7. The composition of claim 1 which further comprises sodium C₉-C₃₀ alkyl sulfate or citric acid.

8. The composition of claim 1 which includes a fumed colloidal silicon dioxide glidant.

9. The composition of claim 1 wherein the therapeutic agent is acyclovir.

10. The composition of claim 1 wherein the therapeutic agent is dihydroergotamine.

11. The composition of claim 1 wherein the therapeutic agent is methylphenidate.

12. The composition of claim 1 which is coated with an immediate release sustained-release or enteric-release coating.

13. The composition of claim 1 wherein the therapeutic agent is selected from a peptide, protein, analog or mimetic thereof.

14. The composition of claim 13 wherein the therapeutic agent is selected from the group consisting of LHRH, TRH, vasopressin, leuprolide, desmopressin, calcitonin, parathyroid hormone, erythropoietin, enkephalin, growth hormone and interferon.

15. The composition of claim 1 wherein the therapeutic agent is an immunoactive agent selected from the group consisting of peptides, proteins, glycopolysaccharides and glycoproteins, as well as fragments and analogs with similar immunoactivity and at least 90% structural homology to the analog or fragment.

16. A pharmaceutical composition which comprises a plurality of the solid beadlets of claim 1 in a pharmaceutically acceptable carrier.

17. The composition of claim 16 wherein the beadlets contains a therapeutic agent selected from the group consisting of LHRH, leuprolide, desmopressin, calcitonin, parathyroid hormone and erythropoietin.

18. The composition of claim 15 which includes a fumed colloidal silicon dioxide glidant.

19. The composition of claim 15 which is in the form of a tablet.
20. The composition of claim 15 which is in the form of a buccal tablet.
21. The composition of claim 12 which is in the form of encapsulated single phase solid solution beadlets.
22. The composition of claim 1 wherein the surfactant is a liquid surfactant.

FIG. 1





FIG. 2



SUBSTITUTE SHEET (RULE 26)

FIG. 3




FIG. 4




FIG. 5




FIG. 6

Acyclovir Beadlet Dissolution
PD0030-40 & PD0030-49
n=3; pH 7.5 Phosphate Buffer
100 RPM





FIG. 7

Acyclovir Beadlet Dissolution
PD0030-52 & PD0030-54
n=3; pH7.5 Phosphate Buffer
100 RPM



F | G. 8

Acyclovir Beadlet Dissolution

PD0030-69

n=3; pH 7.5 Phosphate Buffer






FIG. 9



Acyclovir Beadlet Dissolution

PD0030-85 & PD0030-98
n=3; pH 7.5 Phosphate Buffer
100 RPM




Acyclovir Tablet Dissolution

PD0029-40 & PD0029-41A

n=3; pH 7.5 Phosphate Buffer

100 RPM

FIG. 11



Acyclovir Tablet Dissolution
 PD0029 - 41B & PD0029-41C
 n=3; pH 7.5 Phosphate Buffer
 100RPM

FIG. 12





FIG. 13



Acyclovir Tablet Dissolution
 PD0029-54A & PD0029-54B
 n=3; pH 7.5 Phosphate Buffer
 100 RPM





FIG. 15

Acyclovir Tablet Dissolution

PD0029-54C & PD0029-55A
n=3; pH 7.5 Phosphate Buffer
100 RPM



Acyclovir Tablet Dissolution
 PD0029-55B & PD0029-55C
 n=3; pH 7.5 Phosphate Buffer
 100 RPM

FIG. 16





FIG. 17

Acyclovir Beadlet Dissolution
PD0029-55D & PD0029-56A
n=3; pH 7.5 Phosphate Buffer
100 RPM



Acyclovir Tablet Dissolution
PD0033-55
n=3; pH 7.5 Phosphate Buffer
100 RPM

FIG. 18






FIG. 19



SUBSTITUTE SHEET (RULE 28)

FIG. 20



SUBSTITUTE SHEET (RULE 26)

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A3	(11) International Publication Number: WO 99/13864 (43) International Publication Date: 25 March 1999 (25.03.99)
(21) International Application Number:	PCT/US98/19658	(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date:	18 September 1998 (18.09.98)	
(30) Priority Data:	60/059,408 19 September 1997 (19.09.97) US	Published <i>With international search report.</i>
(71) Applicant:	SHIRE LABORATORIES, INC. [US/US]; 1550 East Guide Drive, Rockville, MD 20850 (US).	(88) Date of publication of the international search report: 12 August 1999 (12.08.99)
(72) Inventors:	BURNSIDE, Beth, A.; 1808 Briggs Chaney Road, Silver Spring, MD 20905 (US). MC GUINNESS, Charlotte, M.; 6510 Broxborn Drive, Bethesda, MD 20817 (US). RUDNIC, Edward, M.; 15103 Gravenstein Way, North Potomac, MD 20878 (US). COUCH, Richard, A.; Apartment 1021, 7620 Old Georgetown Road, Bethesda, MD 20814 (US). GUO, Xiaodi; 7201 Dubuque Court, Rockville, MD 20855 (US). TUSTIAN, Alexander, K.; Apartment I302, 3927 243rd Place, Northeast, Bothell, WA 98021 (US).	
(74) Agents:	OLSTEIN, Elliot, M. et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).	
(54) Title:	SOLID SOLUTION BEADLET	
(57) Abstract	<p>Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent, which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100 °C, and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolized glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.</p>	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/19658

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/16, A61K 31/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPODOC, WPI, US PAT FULL, CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0448930 A1 (AMERICAN CYANAMID COMPANY), 2 October 1991 (02.10.91), page 3, line 26 - line 53; page 3, line 58 - page 4, line 3, claims --	1-22
X	WO 9107171 A1 (NOVA PHARMACEUTICAL CORPORATION), 30 May 1991 (30.05.91), claims --	1-22
X	WO 9427557 A2 (SMITHKLINE BEECHAM CORPORATION), 8 December 1994 (08.12.94), page 12, line 3 - page 13, line 3, claims --	1-22

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

Date of mailing of the international search report

9 February 1999

30.03.99

Name and mailing address of the ISA/

Authorized officer

European Patent Office, P.O. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

ANNELI JÖNSSON
Telephone No.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US 98/19658
--

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9412180 A1 (SMITHKLINE BEECHAM PLC), 9 June 1994 (09.06.94), page 2, line 21 - page 4, line 2 --	1-22
A	WO 9525505 A1 (PHARMAVENE, INC.), 28 Sept 1995 (28.09.95), page 5, line 21 - page 6, line 8, claims -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

21/12/98

International application No.

PCT/US 98/19658

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9412180 A1	09/06/94	AU 5563494 A		22/06/94
		CN 1095923 A		07/12/94
		EP 0670722 A		13/09/95
		JP 8503482 T		16/04/96
		US 5597844 A		28/01/97
		ZA 9308825 A		25/05/95
WO 9525505 A1	28/09/95	AU 1992595 A		09/10/95
		CA 2185802 A		28/09/95
		EP 0750494 A		02/01/97
		JP 9510708 T		28/10/97
		US 5430021 A		04/07/95

THIS PAGE BLANK (USPTO)